Faers | List of Frontiers open access articles

Original Research

Published on 07 Aug 2018

Detecting Pharmacovigilance Signals Combining Electronic Medical Records With Spontaneous Reports: A Case Study of Conventional Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis

in Drugs Outcomes Research and Policies

Liwei Wang
Majid Rastegar-Mojarad
Zhiliang Ji
Sijia Liu
Ke Liu
Sungrim Moon
Feichen Shen
Yanshan Wang
Lixia Yao
John M. Davis III

Frontiers in Pharmacology

doi 10.3389/fphar.2018.00875

11,213 views
35 citations

Original Research

Published on 20 May 2021

Assessment of the Safety Signal for the Abuse Potential of Pregabalin and Gabapentin Using the FAERS Database and Big Data Search Analytics

in Addictive Disorders

Georgios Papazisis
Dimitrios Spachos
Spyridon Siafis
Niki Pandria
Eleni Deligianni
Ioannis Tsakiridis
Antonios Goulas

Frontiers in Psychiatry

doi 10.3389/fpsyt.2021.640264

8,686 views
13 citations

Original Research

Published on 01 Apr 2025

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database

in Inflammation Pharmacology

Xueping Shi
Chen Wang
Xiang Liu
Li Zou
Pei Guo

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1558868

5,303 views
5 citations

Hypothesis and Theory

Published on 05 Jan 2024

RxNorm for drug name normalization: a case study of prescription opioids in the FDA adverse events reporting system

in Integrative Bioinformatics

Huyen Le
Ru Chen
Stephen Harris
Hong Fang
Beverly Lyn-Cook
Huixiao Hong
Weigong Ge
Paul Rogers
Weida Tong
Wen Zou

Frontiers in Bioinformatics

doi 10.3389/fbinf.2023.1328613

5,982 views
9 citations

Original Research

Accepted on 03 Jun 2026

Comparative Safety Profile of Biktarvy: Insights from a Clinical Cohort and the FAERS Database

in Pharmacology of Infectious Diseases

Xinmei Pan
Qingqing Tian
Qian Wang
Linli Xie
Jiangchuan Xie

Frontiers in Pharmacology

Original Research

Published on 02 Jul 2024

Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database

in Pharmacoepidemiology

Feng Liu
Jing-xuan Zheng
Xiao-dan Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1365706

7,639 views
12 citations

Original Research

Published on 14 Mar 2023

Pneumatosis intestinalis post steroid use in a patient with immune-related adverse events: Case report, literature review and FAERS analysis

in Pharmacology of Anti-Cancer Drugs

Tingting Zhang
Mingnan Cao
Bin Zhao
Chen Pan
Li Lin
Chuanhao Tang
Zhigang Zhao
Jingli Duan
Li Wang
Jun Liang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1133551

6,419 views
12 citations

Original Research

Published on 27 Nov 2025

Disproportionality analysis of taste disorders using the FDA adverse event reporting system and Japanese adverse drug event report databases

in Pharmacoepidemiology

Yoji Kyotani
Kiichi Nakahira
Masanori Yoshizumi

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1659746

2,476 views
2 citations

Original Research

Published on 19 Sep 2025

Exploring the top 30 drugs associated with drug-induced thrombotic microangiopathy based on the FDA adverse event reporting system

in Pharmacology of Anti-Cancer Drugs

Yi Yin
Fanmin Meng
Yanjiao Fan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1658963

3,760 views

Original Research

Published on 10 Jun 2024

Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)

in Drugs Outcomes Research and Policies

Ruibo Li
Xingyue Yuan
Xi Chen
Yili Ou
Jin Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1358592

12,503 views
7 citations

Original Research

Published on 25 Oct 2024

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)

in Drugs Outcomes Research and Policies

Jiahong Zhong
Xihui Yu
Zhuomiao Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1486597

4,667 views
4 citations

Original Research

Published on 05 Jan 2026

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab

in Inflammation Pharmacology

Zhuomiao Lin
Xihui Yu
Meiqing Yang
Jialan Xu
Jiahong Zhong

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1714173

2,676 views
1 citation

Systematic Review

Published on 16 Dec 2024

Fatal outcome related to drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis of FAERS database and a systematic review of cases

in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

Chunsu Liang
Pengjiao An
Yizhou Zhang
Xin Liu
Bo Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2024.1490334

8,531 views
9 citations

Original Research

Published on 26 Mar 2025

Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024

in Pharmacoepidemiology

Jiali Xia
Jing Zhang
Hongyu Zhu
Li Ding

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1565480

5,853 views
2 citations

Original Research

Published on 05 Feb 2026

Comparative safety of denosumab and romosozumab in osteoporosis: an analysis based on the FDA adverse event reporting system database

in Rheumatology

Jian Sun
Ciren Lunzhu
Yao Wu
Jun Li

Frontiers in Medicine

doi 10.3389/fmed.2026.1766601

2,878 views

Original Research

Published on 10 Jul 2024

Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis

in Drugs Outcomes Research and Policies

Zheng Zhang
Qianzhi Yang
Minghao Chen
Wah Yang
Yuping Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1385651

6,941 views
2 citations

Articles

Detecting Pharmacovigilance Signals Combining Electronic Medical Records With Spontaneous Reports: A Case Study of Conventional Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis

Assessment of the Safety Signal for the Abuse Potential of Pregabalin and Gabapentin Using the FAERS Database and Big Data Search Analytics

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database

RxNorm for drug name normalization: a case study of prescription opioids in the FDA adverse events reporting system

Comparative Safety Profile of Biktarvy: Insights from a Clinical Cohort and the FAERS Database

Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database

Pneumatosis intestinalis post steroid use in a patient with immune-related adverse events: Case report, literature review and FAERS analysis

Disproportionality analysis of taste disorders using the FDA adverse event reporting system and Japanese adverse drug event report databases

Exploring the top 30 drugs associated with drug-induced thrombotic microangiopathy based on the FDA adverse event reporting system

Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab

Fatal outcome related to drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis of FAERS database and a systematic review of cases

Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024

Comparative safety of denosumab and romosozumab in osteoporosis: an analysis based on the FDA adverse event reporting system database

Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis